52 related articles for article (PubMed ID: 33039851)
21. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.
Wakimoto H; Tanaka S; Curry WT; Loebel F; Zhao D; Tateishi K; Chen J; Klofas LK; Lelic N; Kim JC; Dias-Santagata D; Ellisen LW; Borger DR; Fendt SM; Vander Heiden MG; Batchelor TT; Iafrate AJ; Cahill DP; Chi AS
Clin Cancer Res; 2014 Jun; 20(11):2898-909. PubMed ID: 24714777
[TBL] [Abstract][Full Text] [Related]
22. Genetic alterations in non-syndromic, familial gliomas in first degree relatives: A systematic review.
Vasilica AM; Sefcikova V; Samandouras G
Clin Neurol Neurosurg; 2020 Nov; 198():106222. PubMed ID: 33039851
[TBL] [Abstract][Full Text] [Related]
23. Molecular Classification of Diffuse Gliomas.
Kalidindi N; Or R; Babak S; Mason W
Can J Neurol Sci; 2020 Jul; 47(4):464-473. PubMed ID: 31918786
[TBL] [Abstract][Full Text] [Related]
24. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
Chen R; Cohen AL; Colman H
Curr Treat Options Oncol; 2016 Aug; 17(8):42. PubMed ID: 27334978
[TBL] [Abstract][Full Text] [Related]
25. Molecular diagnostics of gliomas.
Nikiforova MN; Hamilton RL
Arch Pathol Lab Med; 2011 May; 135(5):558-68. PubMed ID: 21526954
[TBL] [Abstract][Full Text] [Related]
26. Systematic Review of Molecular Targeted Therapies for Adult-Type Diffuse Glioma: An Analysis of Clinical and Laboratory Studies.
Muzyka L; Goff NK; Choudhary N; Koltz MT
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445633
[TBL] [Abstract][Full Text] [Related]
27. [Malignant glioma].
Okamura K
Nihon Rinsho; 1995 Nov; 53(11):2678-83. PubMed ID: 8538025
[TBL] [Abstract][Full Text] [Related]
28. [How molecular biology can improve the clinical diagnosis of gliomas?].
D'Haene N; Blanchard O; De Nève N; Evens J; Maris C; Rorive S; Le Mercier M; Salmon I
Rev Med Brux; 2016; 37(3):152-158. PubMed ID: 28525188
[TBL] [Abstract][Full Text] [Related]
29. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
Jha P; Suri V; Jain A; Sharma MC; Pathak P; Jha P; Srivastava A; Suri A; Gupta D; Chosdol K; Chattopadhyay P; Sarkar C
Neurosurgery; 2010 Dec; 67(6):1681-91. PubMed ID: 21107199
[TBL] [Abstract][Full Text] [Related]
30. Association Between IDH1 and IDH2 Mutations and Preoperative Seizures in Patients with Low-Grade Versus High-Grade Glioma: A Systematic Review and Meta-Analysis.
Phan K; Ng W; Lu VM; McDonald KL; Fairhall J; Reddy R; Wilson P
World Neurosurg; 2018 Mar; 111():e539-e545. PubMed ID: 29288860
[TBL] [Abstract][Full Text] [Related]
31. Molecular genetics of low-grade gliomas: genomic alterations guiding diagnosis and therapeutic intervention. 11th annual Frye-Halloran Brain Tumor Symposium.
Jones PS; Dunn GP; Barker FG; Curry WT; Hochberg FH; Cahill DP
Neurosurg Focus; 2013 Feb; 34(2):E9. PubMed ID: 23373454
[TBL] [Abstract][Full Text] [Related]
32. Neuropathological and molecular aspects of low-grade and high-grade gliomas.
Michotte A; Neyns B; Chaskis C; Sadones J; In 't Veld P
Acta Neurol Belg; 2004 Dec; 104(4):148-53. PubMed ID: 15742604
[TBL] [Abstract][Full Text] [Related]
33. Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas.
Chen R; Ravindra VM; Cohen AL; Jensen RL; Salzman KL; Prescot AP; Colman H
Neurosurg Focus; 2015 Mar; 38(3):E2. PubMed ID: 25727224
[TBL] [Abstract][Full Text] [Related]
34. [Diagnosis and prognosis of gliomas--current prospects of molecular diagnostics].
Haapasalo J; Hyartt A; Salmi M; Nordfors K; Lahtela SL; Kähkönen M; Helén P; Haapasalo H
Duodecim; 2014; 130(9):893-901. PubMed ID: 24881141
[TBL] [Abstract][Full Text] [Related]
35. The clinicopathological and prognostic significance of TP53 alteration in K27M mutated gliomas: an individual-participant data meta-analysis.
Dong C; Yuan Z; Li Q; Wang Y
Neurol Sci; 2018 Jul; 39(7):1191-1201. PubMed ID: 29651718
[TBL] [Abstract][Full Text] [Related]
36. Classification of adult diffuse gliomas by molecular markers-a short review with historical footnote.
Otani R; Uzuka T; Ueki K
Jpn J Clin Oncol; 2017 Jan; 47(1):2-6. PubMed ID: 27799281
[TBL] [Abstract][Full Text] [Related]
37. Prediction of Tumor Development and Urine-Based Liquid Biopsy for Molecule-Targeted Therapy of Gliomas.
Kurimoto M; Rockenbach Y; Kato A; Natsume A
Genes (Basel); 2023 May; 14(6):. PubMed ID: 37372381
[TBL] [Abstract][Full Text] [Related]
38. Clinical and Molecular Features of Patients with Gliomas Harboring IDH1 Non-canonical Mutations: A Systematic Review and Meta-Analysis.
Di Nunno V; Franceschi E; Tosoni A; Gatto L; Maggio I; Lodi R; Angelini D; Bartolini S; Brandes AA
Adv Ther; 2022 Jan; 39(1):165-177. PubMed ID: 34853984
[TBL] [Abstract][Full Text] [Related]
39. [Genetics and brain gliomas].
Alentorn A; Labussière M; Sanson M; Delattre JY; Hoang-Xuan K; Idbaih A
Presse Med; 2013 May; 42(5):806-13. PubMed ID: 22789312
[TBL] [Abstract][Full Text] [Related]
40. Biology and treatment of gliomas.
Janus TJ; Kyritsis AP; Forman AD; Levin VA
Ann Oncol; 1992 Jun; 3(6):423-33. PubMed ID: 1498059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
